On Tuesday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk A/S’s (NYSE:NVO) semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering heart problems or strokes. This medicine, a GLP-1 receptor agonist, was already approved for use in the treatment of obesity and weight management, alongside diet, physical activity, and behavioral support. Also Read Oral Weight Loss Drugs Vs. Injections – Pills Are Promising Yet Challenging Frontier. The approval means that semaglutide is the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack, and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. The approval is based on new data from a post-approval ...